Dienogest
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Menorrhagia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Pregnadien derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dienogest with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pipecuronium BromideExisting use: Other quaternary ammonium compounds42.9% AI-predicted activityagainst K. pneumoniae5 registered studies
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more42.9% AI-predicted activityagainst K. pneumoniae21 registered studies
- CabergolineExisting use: Hypothalamic neoplasm, Parkinson disease42.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more42.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder42.6% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vecuronium BromideExisting use: Other quaternary ammonium compounds42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease42.0% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia41.9% AI-predicted activityagainst K. pneumoniae6 registered studies
- RepotrectinibExisting use: Cancer, Neoplasm41.8% AI-predicted activityagainst K. pneumoniae17 registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis41.7% AI-predicted activityagainst K. pneumoniae25 registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more41.5% AI-predicted activityagainst K. pneumoniae19 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy and Safety Study of an Oral Contraceptive in Healthy Females
NCT00206583 · start 2005-03
Registered record
- Registry ID
- NCT00206583
- Conditions
- Contraception
- Interventions
- EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2007-07
- Enrolment
- 499
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionContraceptionInterventionEV/DNG (Qlaira, BAY86-5027, SH T00658ID)PhasePhase 3Registry statusCompletedStudy on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa
NCT00280657 · start 2004-03-10
Registered record
- Registry ID
- NCT00280657
- Conditions
- Acne Vulgaris
- Interventions
- Valette; Diane; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-03-10
- Completion
- 2005-05-21
- Enrolment
- 1,326
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionValette; Diane; PlaceboPhasePhase 3Registry statusCompletedBleeding Pattern Study
NCT00302666 · start 2003-06
Registered record
- Registry ID
- NCT00302666
- Conditions
- Oral Contraceptive
- Interventions
- Valette (Dienogest/EE30, BAY86-5038); Valette (Dienogest/EE30, BAY86-5038)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-06
- Completion
- 2005-02
- Enrolment
- 1,315
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOral ContraceptiveInterventionValette (Dienogest/EE30, BAY86-5038); Valette (Dienogest/EE30, BAY86-5038)PhasePhase 3Registry statusCompletedOvulation Inhibition of Two 4-phasic Oral Contraceptive Regimens
NCT00805415 · start 2003-03
Registered record
- Registry ID
- NCT00805415
- Conditions
- Ovulation Inhibition
- Interventions
- EV/DNG (Qlaira, BAY86-5027, SH T00658K); EV/DNG (SH T00658L)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-03
- Completion
- 2004-02
- Enrolment
- 209
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOvulation InhibitionInterventionEV/DNG (Qlaira, BAY86-5027, SH T00658K); EV/DNG (SH T00658L)PhasePhase 2Registry statusCompletedFat Distribution in Healthy Early Postmenopausal Women
NCT00335218 · start 2002-07
Registered record
- Registry ID
- NCT00335218
- Conditions
- Healthy; Postmenopause
- Interventions
- Climodien / Lafamme (BAY86-5027); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-07
- Completion
- 2004-08
- Enrolment
- 67
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy; PostmenopauseInterventionClimodien / Lafamme (BAY86-5027); PlaceboPhasePhase 4Registry statusCompleted